If you are a fan of buy and hold investing, then it could be worth checking out the ASX 200 growth shares in this article.
That's because they have been named as buys by brokers and tipped to have very bright long term growth outlooks.
Here's what they are recommending to clients:
Life360 Inc (ASX: 360)
The first ASX 200 growth share that could be a top buy is Life360. It is a rapidly growing location technology company that impressed the market with its second quarter update this month.
Life360 posted a 36% increase in revenue to US$115.4 million and a 36% jump in annualised monthly revenue to US$416.1 million. This was driven by a 25% lift in monthly active users to 88 million and 2.5 million paying circles.
The team at Bell Potter responded very positively to its results, highlighting that "2Q2025 revenue of US$115.4m was 6% ahead of our forecast of US$109.1m and adjusted EBITDA of US$20.3m was 59% above our forecast of US$12.8m. The key metrics of global MAUs, total paying circles, ARPPC and AMR were all close to in line with our forecasts."
As a result, the broker has retained its buy rating with a $47.50 price target.
Light & Wonder Inc (ASX: LNW)
Another ASX 200 growth share that could be a buy is Light & Wonder.
It is a gaming technology that operates across three segments: land-based gaming machines, social gaming, and digital iGaming platforms.
This is a great space to be in, with the company benefitting from a growing global appetite for immersive and mobile-friendly casino gaming. Its digital division, in particular, is experiencing strong growth as more jurisdictions open up to online betting and gaming platforms.
Macquarie is bullish on the company despite near term growth concerns. It notes that "it is easy to be cautious on LNW in the near term (i.e., guidance risks, litigation & leverage), but stepping back, we forecast 16% average annual EPSA (FY25-28E) with the stock trading on 12.5x 12m fwd P/E. With price discovery moving to Australia, a re-rate is likely."
The broker has an outperform rating and $180.00 price target on its shares.
Telix Pharmaceuticals Ltd (ASX: TLX)
A third ASX 200 growth share that could be a top buy is Telix Pharmaceuticals.
It focuses on radiopharmaceuticals, which are targeted therapies and imaging tools used in cancer diagnostics and treatment.
It is already generating significant revenue from its flagship product, Illuccix, and looks well-placed for further growth thanks to its R&D pipeline.
In respect to the latter, Bell Potter highlights that "the data supporting the approval of Zircaix is gold standard and we believe the BLA is likely to receive approval. ccRCC is an attractive market (TAM~US$500m) with margins likely to be more lucrative than the current GP margin for the group."
Bell Potter has a buy rating and $33.00 price target on its shares.
